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adequate patient preparation in terms of dietary restrictions
which could impede test accuracy. There were inconsistencies
among physicians regarding when in a patient’s life to initiate
screening, and at what age to discontinue screening. CONCLU-
SIONS: This systematic review of ten included studies reﬂected
considerable knowledge gaps among physicians, which could
contribute to reasons for inadequate screening rates. Provider
education about CRC screening should emphasize guidelines
regarding when to start screening, frequency rates for screening
with given modalities, and particular techniques and precautions
that should be used to perform screening.
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COSTS WHEN THE ERRORS PRESENT HETEROSKEDASTICITY
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OBJECTIVE: Log transformation reduces robustness by focus-
ing on symmetry. It improves precision and it diminishes the
outlier effect. One big disadvantage of log models is retrans-
formation problems. Although smearing methods provides 
non-parametric way to transform estimated costs, it fails to
adjust heteroskedasticity especially if the form of heteroskedas-
ticity is not known. In this paper, we propose a method where
we can apply transformation accounting for heteroskedasticity.
We compare our results with smearing estimators and general-
ized linear model (GLM) estimators. METHODS: Two form of
heteroskedasticity is considered: 1) The heteroskedasticity is
known up to a multiple constant. We used generalized least
squares (GLS) estimator for correcting heteroskedasticity: and 2)
The form of heteroskedasticity is unknown. If this is the case,
feasible GLS method is used. After correcting for heteroskedas-
ticity smearing estimates is applied for the transformed equations
to do the retransformation. Medstat Market Scan data is used
to show the application. Cost level estimators are compared:
OLS estimation, smearing transformation assumed no het-
eroskedasticity, smearing transformation with heteroskedasticity,
GLM estimators where the family is gaussian with logarithmic
link function. RESULTS: Estimation methods yield that log scale
residuals were heavy tailed. White Test suggested the presence of
heteroskedascity. The graph of squared residuals on disease stage
levels show that variance is increasing with an increased level of
stage levels. Park test suggested that if GLM is chosen, gaussian
family should be chosen. Comparisons of the retransformed
costs yield that smearing transformation after accounting for
least deviation yielded least minimum square errors. CONCLU-
SION: We attempted to solve the biggest disadvantage of log
transformed cost estimation by proposing two stage estimation
procedure where at the ﬁrst stage GLS or feasible GLS is used to
correct for possible heteroskedasticity (depending on the form 
of heteroskedasticity), at the second stage smearing method is
applied to transformed equation.
PCN22
ESTIMATION OF CENSORED MEDICAL COUNT DATA
Baser O
Medstat, Inc, Ann Arbor, MI, USA
OBJECTIVE: Censoring is common problem with medical count
data. Estimation over only uncensored patients yields bias
toward the patients who have shorter survival time since patients
who have longer survival times are high likely to be censored.
Standard survival analysis is not applicable since the number of
visits during the study time and after censoring time is not inde-
pendent. The objective of this paper is to propose a method,
which can be applied to censored count data. METHOD: The
proposed method ﬁrst estimates the probability of censoring 
by using logit model. Then, second stage involves estimating
weighted Poisson regression where weights are calculated as
inverse of estimated probability of censoring. We show that the
resulting estimators are consistent. Standard errors from second
stage are not valid and should be adjusted for ﬁrst stage estima-
tion. We estimate the errors by using bootstrapping techniques.
RESULTS: Medstat Market Scan data is used as an application
of the method. Total hospitalization days after a year of initial
diagnoses is estimated. Patients who are diagnosed less than a
year before the end of study period are considered as censored.
After using inverse probability weighted poisson regression, we
also estimate the total hospitalization days by dropping the
patients whose visits are censored. A test is proposed to compare
the coefﬁcients. We found that the difference in coefﬁcients are
signiﬁcant (p < 0.0004). CONCLUSION: This paper presents a
method for testing and correcting for possible sample selection
bias for cross sectional data. In our application we assessed the
inﬂuence of explanatory variables, such as patient and clinical
characteristics, on inpatient visits of asthma two years following
diagnosis after accounting for possible selection bias due to 
censoring. We applied poisson and our proposed method and 
to show that failing to do the adjustments yield different 
estimators.
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OBJECTIVES: To assess inter-rater agreement of Health Utilities
Index (HUI) measurements in survivors of cancer during child-
hood in Honduras, El Salvador, Nicaragua and Panama.
METHODS: Patients and their parents completed a Spanish-
language interviewer-administered HUI questionnaire. Physi-
cians answered the Spanish-language self-complete questionnaire
version. Primary analyses of agreement between patients and
parents, and patients and physicians, for HUI3 single-attribute
and overall health-related quality of life (HRQL) utility scores
was measured using single-measure one-way intra-class correla-
tion coefﬁcient (ICC). Secondary analyses used the two-way
mixed model ICC, Pearson’s r and concordance correlation coef-
ﬁcient. Differences in mean scores > 0.05 are considered clini-
cally important. RESULTS: Of 211 patients surveyed (aged 3.4
to 25.8 years at time of study, 56% male), there were 191
patient/parent pairs of complete HUI assessments and 192
patient/physician pairs. There was moderate or better agreement
(ICC > 0.41, p < 0.001) between both pairs of raters for vision,
hearing, speech and ambulation. Agreement was less than mod-
erate (ICC < 0.41) for pain (p < 0.01), cognition (p < 0.01) and
emotion (p < 0.05). Statistically signiﬁcant (p < 0.001) and clin-
ically important differences were observed within both sets of
paired groups for cognition and emotion, with lower mean
scores for patients. For overall HRQL, agreement was moderate
between patients and parents but less than moderate between
patients and physicians. The mean overall HRQL score was sig-
niﬁcantly lower statistically (p < 0.01) and clinically for patients
than both parents (diff = 0.094), and physicians (diff = 0.159).
Secondary analyses yielded similar results. CONCLUSIONS:
Parent and physician reports should not be considered inter-
changeable with patient assessments, especially for aspects of
health not readily observable. There were important differences
between patients and parents and physicians in emotion, cogni-
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tion, pain and overall HRQL with patients reporting more mor-
bidity. The results are consistent with the published literature.
Future research should focus on intra-rater reliability, respon-
siveness and validity.
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PRO data have now become an integral part of clinical trials to
evaluate the efﬁcacy of treatment for severe and terminal illness.
However, it is often fraught with missing data due to illness,
death and early termination of a trial (time to event study or
superior efﬁcacy). OBJECTIVES: To evaluate different methods
of data imputation when trials are terminated early and there is
missing data due to deteriorating health. METHODS: Using data
from a large cancer (multiple myeloma) trial which included 
both missing data due to illness and early termination due to
study termination or non-illness-related reasons, several statisti-
cal methods were evaluated. A total of 598 subjects completed
the EORTC QLQ-C30 at least one post-baseline timepoint and
were available for analysis. After setting PRO scores of all sub-
jects who died to the worst possible scores, remaining missing
data were imputed and analyzed by either multiple imputation
(M = 4) using a generalized estimating equation technique, Sun
and Song method for censored data, and Pattern-Mixture
models. Global Health was the primary PRO endpoint with all
other scales adjusted for multiplicity using the Hochberg-
Benjamini method. RESULTS: All methods found similar results,
although the multiple imputation method found the most
number of scales/symptoms signiﬁcant (N = 10). Sun and Song
and the Pattern-Mixture model each found the same four scales/
symptoms signiﬁcantly different between groups—Global
Health, Cognitive Functioning, Emotional Functioning and
Dyspnea. CONCLUSIONS: All methods are useful approaches
to handle missing data imputation and analysis. The multiple
imputation method appears to be less conservative, ﬁnding ten
signiﬁcant differences versus four with the other methods. The
Sun and Song approach provides an insight into what the treat-
ment differences would have been had all the subjects stayed in
the study. The Pattern-Mixture model was the most complex
method and did not provide any additional information over the
other methods.
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OBJECTIVES: To assess inter-rater reliability and discriminative
validity of Brazilian Portuguese HUI questionnaires for a sample
of survivors of childhood cancer. METHODS: A sample of 
consecutive patients attending the long-term follow-up clinic 
at Centro de Treatmento e Pesquisa Hospital do Cancer in 
São Paulo was recruited. Self- and proxy-assessment versions of
self-complete, one-week health-status recall HUI questionnaires
were used. A questionnaire was completed independently by
each patient (self-assessment), and nurse and physician (proxy-
assessments). HUI single-attribute utility scores (n = 14) and
health-related quality of life (HRQL) scores (n = 2) were derived
using standard coding algorithms and published utility functions.
Single measure, one-way random effects models were used to cal-
culate intra-class correlations (ICC) of inter-rater agreement.
Analysis of variance (ANOVA) assessed the statistical signiﬁ-
cance (p < 0.05) of differences in mean utility scores for patients
in various diagnostic groups (n = 15). RESULTS: HUI data for
138 cancer survivors (45.7% female) were collected from the
three types of assessors. Patient mean age at diagnosis was 6.3
(min = 0.2, max = 17.4) years and 22.8 (13.4, 40.2) years at
survey. There was substantial to almost perfect agreement 
(ICC > 0.85, p < 0.001) between all pairs of raters for all types
of utility scores. ANOVA detected statistically signiﬁcant (p <
0.013) differences among the diagnostic groups, in means of
HUI2 and HUI3 HRQL utility scores, HUI3 vision (p < 0.0005),
HUI3 ambulation (p = 0.002), HUI2 mobility (p = 0.001) and
HUI2 self-care (p < 0.045). CONCLUSIONS: There was sub-
stantial or better agreement in all single-attribute and HRQL
utility scores between pairs of patient, nurse and physician asses-
sors. Differences in mean HRQL among diagnostic groups is evi-
dence of discriminative validity. The Brazilian Portuguese HUI
questionnaires should be considered for future PRO-studies of
morbidity and HRQL in survivors of cancer in childhood in
Brazil. Future research on the measurement properties of the
Brazilian Portuguese HUI questionnaires should focus on con-
current validity and other health problems.
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OBJECTIVES: The importance of postmarketing surveillance
was again publicized by the recent recall of Vioxx; similar 
concerns should be addressed in trial-based cost-effectiveness
analyses (CEA). The net beneﬁt regression approach applies
econometric methods; thus, offers a power tool to assess CEA of
a new intervention in a non-randomized environment (e.g.,
claims data). Our study proposed a Bayesian approach to syn-
thesize clinical trial data with secondary data collected in post-
marketing setting. METHODS: We ﬁrst compared the treatment
effect estimated from least squares (LS) and Bayesian regressions
using a simulated data of 200 pairs of case-control patients. The
data contained information on cost (C), effectiveness (E), and
demographics for each patient, with 85% of data in the quad-
rant of positive incremental cost and incremental effectiveness.
The dependent variable was the net beneﬁt (NB), calculated as:
lE - C, where l denoted the maximum willingness to pay;
covariates included demographics and a binary variable indicat-
ing treatment. By incorporating trial data in the prior distribu-
tion, we demonstrated use of the Bayesian regression to update
the net beneﬁt estimates with observed data, exempliﬁed by the
simulated data. RESULTS: NB estimated from LS and Bayesian
approaches were very similar when non-informative prior was
used, representing the scenario where the trial data was
neglected. However, using the posterior distribution of the
regression coefﬁcients, the Bayesian approach can infer the prob-
ability that the new treatment was cost-effective. At l = $15,000,
the estimated NB was $679.3 (P = 0.766) in OLS and $677.5 in
Bayesian, with 0.61 probability of cost-effective. When a strong
prior favoring the new treatment was employed, the estimated
NB increased to $3,414 at l = $15,000 and the probability of
